Biotechnology company 53Biologics, specialized in the development and manufacturing of biologic drugs, has announced the closing of a strategic funding round led by European private equity firm Ren Life Sciences, with co-investment from existing shareholders, including Spanish innovation fund Inveready.
The capital will allow 53Biologics to consolidate its position as a key player in Europe’s biomanufacturing infrastructure and to advance several strategic initiatives:
Pablo Gutiérrez, CEO of 53Biologics, stated:
"This investment represents a clear endorsement of our vision: to provide flexible, high-quality solutions that accelerate the development and manufacturing of biologic medicines for patients worldwide."
Cristina Moratilla-Martin from Ren Life Sciences said:
"We are very pleased to lead this investment in 53Biologics. The company combines strong technical capabilities with a differentiated position in biologic drug development and manufacturing. We have full confidence in their team and their ability to become a key partner for the international biopharmaceutical industry."
Roger Piqué, Partner at Inveready, added:
"At Inveready, we are proud to continue supporting 53Biologics, a company we have collaborated with since 2018. During this time, they have demonstrated excellent ability to manage growth and consolidate a solid industrial platform, backed by a high-level management and technical team."
Beyond industrial growth, the round will also have a positive impact on the scientific and technological ecosystem through the creation of highly skilled jobs in engineering, quality control, and process development, reinforcing the biopharmaceutical industry’s capacity to meet current challenges.
About 53Biologics
53Biologics is a CDMO (Contract Development and Manufacturing Organization) specialized in biologic drug development and manufacturing, from DNA to proteins. The company offers services from preclinical development to GMP manufacturing, accelerating the time-to-market for its clients’ biologic drugs
cloud technology axon
With a target size of €250 million, the fund aims to complete betwee...
Capital-Riesgo.es
Subscribe to our newsletter and stay up to date with the latest news and deals!
2013 © Capital-Riesgo.es - Site Developments SL. All Rights Reserved. Terms of Service | Privacy Policy
Articles
Directory
